Effects of icariin on cell injury and glucocorticoid resistance in BEAS‑2B cells exposed to cigarette smoke extract

Hu,Lingli; Liu,Feng; Li,Lulu; Zhang,Li; Yan,Chen; Li,Qiuping; Qiu,Jian; Dong,Jingcheng; Sun,Jing; Zhang,Hongying

doi:10.3892/etm.2020.8702

Effects of icariin on cell injury and glucocorticoid resistance in BEAS‑2B cells exposed to cigarette smoke extract

Authors:
- Lingli Hu
- Feng Liu
- Lulu Li
- Li Zhang
- Chen Yan
- Qiuping Li
- Jian Qiu
- Jingcheng Dong
- Jing Sun
- Hongying Zhang
View Affiliations

Affiliations: Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China, Department of Rehabilitation, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Published online on: April 29, 2020 https://doi.org/10.3892/etm.2020.8702
Pages: 283-292
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glucocorticoids (GCs) exert a therapeutic effect in numerous chronic inflammatory diseases. However, chronic obstructive pulmonary disease (COPD) tends to be GC‑resistant. Icariin, a major component of flavonoids isolated from Epimedium brevicornum Maxim (Berberidaceae), significantly relieves symptoms in patients with COPD. However, the mechanism of action remains unclear and further investigation is required to establish whether it may serve as an alternative or complementary therapy for COPD. The aim of the present study was to determine the effects of icariin in human bronchial epithelial cells exposed to cigarette smoke extract (CSE) and to determine whether icariin reverses GC resistance. The results revealed that icariin significantly increased the proliferation of CSE‑exposed cells. Furthermore, icariin significantly increased protein expression of the anti‑inflammatory factor interleukin (IL)‑10 and significantly decreased protein expression of the pro‑inflammatory factors IL‑8 and tumor necrosis factor α. Icariin also attenuated the expression of the cellular matrix remodelling biomarkers matrix metallopeptidase 9 and tissue inhibitor of metalloproteinase 1, and decreased the production of reactive oxygen species (ROS). In addition, icariin regulated the expression of GC resistance‑related factors, such as GC receptors, histone deacetylase 2, nuclear factor erythroid‑2‑related factor 2 and nuclear factor κ B. The results obtained in the present study suggested that icariin may decrease CSE‑induced inflammation, airway remodelling and ROS production by mitigating GC resistance. In conclusion, icariin may potentially be used in combination with GCs to increase therapeutic efficacy and reduce GC resistance in COPD.

View Figures

View References

1	Mathers CD and Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3(e442)2006.PubMed/NCBI View Article : Google Scholar
2	Hanania NA and Marciniuk DD: A unified front against COPD: Clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society. Chest. 140:565–566. 2011.PubMed/NCBI View Article : Google Scholar
3	Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 176:532–555. 2007.PubMed/NCBI View Article : Google Scholar
4	Aghapour M, Raee P, Moghaddam SJ, Hiemstra PS and Heijink IH: Airway epithelial barrier dysfunction in chronic obstructive pulmonary disease: Role of cigarette smoke exposure. Am J Respir Cell Mol Biol. 58:157–169. 2018.PubMed/NCBI View Article : Google Scholar
5	Ng DS, Liao W, Tan WS, Chan TK, Loh XY and Wong WS: Anti-malarial drug artesunate protects against cigarette smoke-induced lung injury in mice. Phytomedicine. 21:1638–1644. 2014.PubMed/NCBI View Article : Google Scholar
6	Murray LA, Dunmore R, Camelo A, Da Silva CA, Gustavsson MJ, Habiel DM, Hackett TL, Hogaboam CM, Sleeman MA and Knight DA: Acute cigarette smoke exposure activates apoptotic and inflammatory programs but a second stimulus is required to induce epithelial to mesenchymal transition in COPD epithelium. Respir Res. 18(82)2017.PubMed/NCBI View Article : Google Scholar
7	Huang AX, Lu LW, Liu WJ and Huang M: Plasma inflammatory cytokine IL-4, IL-8, IL-10, and TNF-α levels correlate with pulmonary function in patients with asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome. Med Sci Monit. 22:2800–2808. 2016.PubMed/NCBI View Article : Google Scholar
8	Wang C, Li Z, Liu X, Peng Q, Li F, Li D and Wang C: Effect of Liuweibuqi capsule, a Chinese patent medicine, on the JAK1/STAT3 pathway and MMP9/TIMP1 in a chronic obstructive pulmonary disease rat model. J Tradit Chin Med. 35:54–62. 2015.PubMed/NCBI View Article : Google Scholar
9	Marushchak M, Maksiv K and Krynytska I: The specific features of free radical oxidation in patients with chronic obstructive pulmonary disease and arterial hypertension. Pol Merkur Lekarski. 47:95–98. 2019.PubMed/NCBI
10	Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald JM, Gibson P, Ohta K, O'Byrne P, Pedersen SE, et al: Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 31:143–178. 2008.PubMed/NCBI View Article : Google Scholar
11	Barnes PJ, Greening AP and Crompton GK: Glucocorticoid resistance in asthma. Am J Respir Crit Care Med. 152 (Suppl):S125–S140. 1995.PubMed/NCBI View Article : Google Scholar
12	Burmester GR and Pope JE: Novel treatment strategies in rheumatoid arthritis. Lancet. 389:2338–2348. 2017.PubMed/NCBI View Article : Google Scholar
13	Baumgart DC and Sandborn WJ: Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet. 369:1641–1657. 2007.PubMed/NCBI View Article : Google Scholar
14	Torres J, Mehandru S, Colombel JF and Peyrin-Biroulet L: Crohn's disease. Lancet. 389:1741–1755. 2017.PubMed/NCBI View Article : Google Scholar
15	Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, Danese S, D'Hoore A, Gassull M, Gomollón F, et al: The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohn's Colitis. 4:28–62. 2010.PubMed/NCBI View Article : Google Scholar
16	Rhen T and Cidlowski JA: Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med. 353:1711–1723. 2005.PubMed/NCBI View Article : Google Scholar
17	Barnes PJ: New therapies for chronic obstructive pulmonary disease. Med Princ Pract. 19:330–338. 2010.PubMed/NCBI View Article : Google Scholar
18	Morjaria JB, Malerba M and Polosa R: Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD. Drug Discov Today. 15:396–405. 2010.PubMed/NCBI View Article : Google Scholar
19	Barnes PJ: How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol. 148:245–254. 2006.PubMed/NCBI View Article : Google Scholar
20	Rodriguez JM, Monsalves-Alvarez M, Henriquez S, Llanos MN and Troncoso R: Glucocorticoid resistance in chronic diseases. Steroids. 115:182–192. 2016.PubMed/NCBI View Article : Google Scholar
21	Barnes PJ and Adcock IM: Glucocorticoid resistance in inflammatory diseases. Lancet. 373:1905–1917. 2009.PubMed/NCBI View Article : Google Scholar
22	Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM and Barnes PJ: Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med. 200:689–695. 2004.PubMed/NCBI View Article : Google Scholar
23	Barnes PJ, Ito K and Adcock IM: Corticosteroid resistance in chronic obstructive pulmonary disease: Inactivation of histone deacetylase. Lancet. 363:731–733. 2004.PubMed/NCBI View Article : Google Scholar
24	Zhou Z, Zheng W, Liang T, Yan Q, Zhang C, Huang H, Liu X and Ye X: Efficacy and safety of Chuankezhi injection in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis protocol. Medicine (Baltimore). 99(e18620)2020.PubMed/NCBI View Article : Google Scholar
25	Zhao YL, Song HR, Fei JX, Liang Y, Zhang BH, Liu QP, Wang J and Hu P: The effects of Chinese yam-epimedium mixture on respiratory function and quality of life in patients with chronic obstructive pulmonary disease. J Tradit Chin Med. 32:203–207. 2012.PubMed/NCBI View Article : Google Scholar
26	He W, Sun H, Yang B, Zhang D and Kabelitz D: Immunoregulatory effects of the herba Epimediia glycoside icariin. Arzneimittelforschung. 45:910–913. 1995.PubMed/NCBI
27	Shi Y, Yan WH, Lin QY and Wang WM: Icariin influences cardiac remodeling following myocardial infarction by regulating the CD147/MMP-9 pathway. J Int Med Res. 46:2371–2385. 2018.PubMed/NCBI View Article : Google Scholar
28	Dong H, Ming S, Fang J, Li Y and Liu L: Icariin ameliorates angiotensin II-induced cerebrovascular remodeling by inhibiting Nox2-containing NADPH oxidase activation. Hum Cell. 32:22–30. 2019.PubMed/NCBI View Article : Google Scholar
29	Ming LG, Chen KM and Xian CJ: Functions and action mechanisms of flavonoids genistein and icariin in regulating bone remodeling. J Cell Physiol. 228:513–521. 2013.PubMed/NCBI View Article : Google Scholar
30	Xu CQ, Liu BJ, Wu JF, Xu YC, Duan XH, Cao YX and Dong JC: Icariin attenuates LPS-induced acute inflammatory responses: Involvement of PI3K/Akt and NF-kappaB signaling pathway. Eur J Pharmacol. 642:146–153. 2010.PubMed/NCBI View Article : Google Scholar
31	Chen SR, Xu XZ, Wang YH, Chen JW, Xu SW, Gu LQ and Liu PQ: Icariin derivative inhibits inflammation through suppression of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways. Biol Pharm Bull. 33:1307–1313. 2010.PubMed/NCBI View Article : Google Scholar
32	Wu J, Xu H, Wong PF, Xia S, Xu J and Dong J: Icaritin attenuates cigarette smoke-mediated oxidative stress in human lung epithelial cells via activation of PI3K-AKT and Nrf2 signaling. Food Chem Toxicol. 64:307–313. 2014.PubMed/NCBI View Article : Google Scholar
33	Krystosek A and Sachs L: Control of lysozyme induction in the differentiation of myeloid leukemic cells. Cell. 9:675–684. 1976.PubMed/NCBI View Article : Google Scholar
34	Hu L, Yu Y, Huang H, Fan H, Hu L, Yin C, Li K, Fulton DJ and Chen F: Epigenetic regulation of interleukin 6 by histone acetylation in macrophages and its role in paraquat-induced pulmonary Fibrosis. Front Immunol. 7(696)2017.PubMed/NCBI View Article : Google Scholar
35	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
36	Papakonstantinou E, Karakiulakis G, Batzios S, Savic S, Roth M, Tamm M and Stolz D: Acute exacerbations of COPD are associated with significant activation of matrix metalloproteinase 9 irrespectively of airway obstruction, emphysema and infection. Respir Res. 16(78)2015.PubMed/NCBI View Article : Google Scholar
37	Navratilova Z, Kolek V and Petrek M: Matrix metalloproteinases and their inhibitors in chronic obstructive pulmonary disease. Arch Immunol Ther Exp (Warsz). 64:177–193. 2016.PubMed/NCBI View Article : Google Scholar
38	Vandewalle J, Luypaert A, De Bosscher K and Libert C: Therapeutic mechanisms of glucocorticoids. Trends Endocrinol Metab. 29:42–54. 2018.PubMed/NCBI View Article : Google Scholar
39	Li J, Liu D, Wu J, Zhang D, Cheng B, Zhang Y, Yin Z, Wang Y, Du J and Ling C: Ginsenoside Rg1 attenuates ultraviolet B-induced glucocortisides resistance in keratinocytes via Nrf2/HDAC2 signalling. Sci Rep. 6(39336)2016.PubMed/NCBI View Article : Google Scholar
40	Stabile AM, Marinucci L, Balloni S, Giuliani A, Pistilli A, Bodo M and Rende M: Long term effects of cigarette smoke extract or nicotine on nerve growth factor and its receptors in a bronchial epithelial cell line. Toxicol In Vitro. 53:29–36. 2018.PubMed/NCBI View Article : Google Scholar
41	Munakata S, Ishimori K, Kitamura N, Ishikawa S, Takanami Y and Ito S: Oxidative stress responses in human bronchial epithelial cells exposed to cigarette smoke and vapor from tobacco- and nicotine-containing products. Regul Toxicol Pharmacol. 99:122–128. 2018.PubMed/NCBI View Article : Google Scholar
42	Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, Romieu I, Silverman EK and Balmes JR: Committee on Nonsmoking COPD Environmental and Occupational Health Assembly. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 182:693–718. 2010.PubMed/NCBI View Article : Google Scholar
43	Lee H, Jung KH, Park S, Kil YS, Chung EY, Jang YP, Seo EK and Bae H: Inhibitory effects of Stemona tuberosa on lung inflammation in a subacute cigarette smoke-induced mouse model. BMC Complement Altern Med. 14(513)2014.PubMed/NCBI View Article : Google Scholar
44	Ramos CO, Campos KKD, Costa GP, Cangussú SD, Talvani A and Bezerra FS: Taurine treatment decreases inflammation and oxidative stress in lungs of adult mice exposed to cigarette smoke. Regul Toxicol Pharmacol. 98:50–57. 2018.PubMed/NCBI View Article : Google Scholar
45	Chen L, Ge Q, Tjin G, Alkhouri H, Deng L, Brandsma CA, Adcock I, Timens W, Postma D, Burgess JK, et al: Effects of cigarette smoke extract on human airway smooth muscle cells in COPD. Eur Respir J. 44:634–646. 2014.PubMed/NCBI View Article : Google Scholar
46	BéruBé K, Aufderheide M, Breheny D, Clothier R, Combes R, Duffin R, Forbes B, Gaça M, Gray A, Hall I, et al: In vitro models of inhalation toxicity and disease The report of a FRAME workshop. Altern Lab Anim. 37:89–141. 2009.PubMed/NCBI
47	López-Rodríguez JC, Benedé S, Barderas R, Villalba M and Batanero E: Airway epithelium plays a leading role in the complex framework underlying respiratory allergy. J Investig Allergol Clin Immunol. 27:346–355. 2017.PubMed/NCBI View Article : Google Scholar
48	Gras D, Chanez P, Vachier I, Petit A and Bourdin A: Bronchial epithelium as a target for innovative treatments in asthma. Pharmacol Ther. 140:290–305. 2013.PubMed/NCBI View Article : Google Scholar
49	Pouli AE, Hatzinikolaou DG, Piperi C, Stavridou A, Psallidopoulos MC and Stavrides JC: The cytotoxic effect of volatile organic compounds of the gas phase of cigarette smoke on lung epithelial cells. Free Radic Biol Med. 34:345–355. 2003.PubMed/NCBI View Article : Google Scholar
50	Singh S, Verma SK, Kumar S, Ahmad MK, Nischal A, Singh SK and Dixit RK: Correlation of severity of chronic obstructive pulmonary disease with potential biomarkers. Immunol Lett. 196:1–10. 2018.PubMed/NCBI View Article : Google Scholar
51	Zhang X, Zheng H, Zhang H, Ma W, Wang F, Liu C and He S: Increased interleukin (IL)-8 and decreased IL-17 production in chronic obstructive pulmonary disease (COPD) provoked by cigarette smoke. Cytokine. 56:717–725. 2011.PubMed/NCBI View Article : Google Scholar
52	Schneider D, Ganesan S, Comstock AT, Meldrum CA, Mahidhara R, Goldsmith AM, Curtis JL, Martinez FJ, Hershenson MB and Sajjan U: Increased cytokine response of rhinovirus-infected airway epithelial cells in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 182:332–340. 2010.PubMed/NCBI View Article : Google Scholar
53	de Godoy I, Donahoe M, Calhoun WJ, Mancino J and Rogers RM: Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med. 153:633–637. 1996.PubMed/NCBI View Article : Google Scholar
54	Xie J, Yang XY, Shi JD, Deng XQ and Long W: A new inflammation marker of chronic obstructive pulmonary disease-adiponectin. World J Emerg Med. 1:190–195. 2010.PubMed/NCBI
55	Barnes PJ: Therapy of chronic obstructive pulmonary disease. Pharmacol Ther. 97:87–94. 2003.PubMed/NCBI View Article : Google Scholar
56	Wu H, Yang S, Wu X, Zhao J, Zhao J, Ning Q, Xu Y and Xie J: Interleukin-33/ST2 signaling promotes production of interleukin-6 and interleukin-8 in systemic inflammation in cigarette smoke-induced chronic obstructive pulmonary disease mice. Biochem Biophys Res Commun. 450:110–116. 2014.PubMed/NCBI View Article : Google Scholar
57	Malaviya R, Laskin JD and Laskin DL: Anti-TNFα therapy in inflammatory lung diseases. Pharmacol Ther. 180:90–98. 2017.PubMed/NCBI View Article : Google Scholar
58	Zhang L, Cheng Z, Liu W and Wu K: Expression of interleukin (IL)-10, IL-17A and IL-22 in serum and sputum of stable chronic obstructive pulmonary disease patients. COPD. 10:459–465. 2013.PubMed/NCBI View Article : Google Scholar
59	Pelegrino NR, Tanni SE, Amaral RA, Angeleli AY, Correa C and Godoy I: Effects of active smoking on airway and systemic inflammation profiles in patients with chronic obstructive pulmonary disease. Am J Med Sci. 345:440–445. 2013.PubMed/NCBI View Article : Google Scholar
60	Mercer PF, Shute JK, Bhowmik A, Donaldson GC, Wedzicha JA and Warner JA: MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res. 6(151)2005.PubMed/NCBI View Article : Google Scholar
61	Yao H, Hwang JW, Sundar IK, Friedman AE, McBurney MW, Guarente L, Gu W, Kinnula VL and Rahman I: SIRT1 redresses the imbalance of tissue inhibitor of matrix metalloproteinase-1 and matrix metalloproteinase-9 in the development of mouse emphysema and human COPD. Am J Physiol Lung Cell Mol Physiol. 305:L615–L624. 2013.PubMed/NCBI View Article : Google Scholar
62	Greenlee KJ, Werb Z and Kheradmand F: Matrix metalloproteinases in lung: Multiple, multifarious, and multifaceted. Physiol Rev. 87:69–98. 2007.PubMed/NCBI View Article : Google Scholar
63	Tiede SL, Wassenberg M, Christ K, Schermuly RT, Seeger W, Grimminger F, Ghofrani HA and Gall H: Biomarkers of tissue remodeling predict survival in patients with pulmonary hypertension. Int J Cardiol. 223:821–826. 2016.PubMed/NCBI View Article : Google Scholar
64	Vogel ER, Britt RD Jr, Faksh A, Kuipers I, Pandya H, Prakash YS, Martin RJ and Pabelick CM: Moderate hyperoxia induces extracellular matrix remodeling by human fetal airway smooth muscle cells. Pediatr Res. 81:376–383. 2017.PubMed/NCBI View Article : Google Scholar
65	MacDougall JR and Matrisian LM: Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev. 14:351–362. 1995.PubMed/NCBI View Article : Google Scholar
66	Yao PM, Buhler JM, d'Ortho MP, Lebargy F, Delclaux C, Harf A and Lafuma C: Expression of matrix metalloproteinase gelatinases A and B by cultured epithelial cells from human bronchial explants. J Biol Chem. 271:15580–15589. 1996.PubMed/NCBI View Article : Google Scholar
67	LeBert DC, Squirrell JM, Rindy J, Broadbridge E, Lui Y, Zakrzewska A, Eliceiri KW, Meijer AH and Huttenlocher A: Matrix metalloproteinase 9 modulates collagen matrices and wound repair. Development. 142:2136–2146. 2015.PubMed/NCBI View Article : Google Scholar
68	Linder R, Rönmark E, Pourazar J, Behndig A, Blomberg A and Lindberg A: Serum metalloproteinase-9 is related to COPD severity and symptoms-cross-sectional data from a population based cohort-study. Respir Res. 16(28)2015.PubMed/NCBI View Article : Google Scholar
69	Chaudhuri R, McSharry C, Spears M, Brady J, Grierson C, Messow CM, Miele G, Nocka K, MacNee W, Connell M, et al: Sputum matrix metalloproteinase-9 is associated with the degree of emphysema on computed tomography in COPD. Transl Respir Med. 1(11)2013.PubMed/NCBI View Article : Google Scholar
70	Lambert E, Dassé E, Haye B and Petitfrère E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol. 49:187–198. 2004.PubMed/NCBI View Article : Google Scholar
71	Toricelli M, Melo FH, Peres GB, Silva DC and Jasiulionis MG: Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation. Mol Cancer. 12(22)2013.PubMed/NCBI View Article : Google Scholar
72	Arpino V, Brock M and Gill SE: The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biol. 44-46:247–254. 2015.PubMed/NCBI View Article : Google Scholar
73	Mocchegiani E, Giacconi R and Costarelli L: Metalloproteases/anti-metalloproteases imbalance in chronic obstructive pulmonary disease: Genetic factors and treatment implications. Curr Opin Pulm Med. 17 (Suppl 1):S11–S19. 2011.PubMed/NCBI View Article : Google Scholar
74	Pryor WA and Stone K: Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci. 686:12–27; discussion 27-28. 1993.PubMed/NCBI View Article : Google Scholar
75	Boukhenouna S, Wilson MA, Bahmed K and Kosmider B: Reactive oxygen species in chronic obstructive pulmonary disease. Oxid Med Cell Longev. 2018(5730395)2018.PubMed/NCBI View Article : Google Scholar
76	Jiang Y, Wang X and Hu D: Mitochondrial alterations during oxidative stress in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 12:1153–1162. 2017.PubMed/NCBI View Article : Google Scholar
77	MacNee W: Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2:50–60. 2005.PubMed/NCBI View Article : Google Scholar
78	Barnes PJ: Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol. 120:76–85. 2010.PubMed/NCBI View Article : Google Scholar
79	Ingawale DK, Mandlik SK and Patel SS: An emphasis on molecular mechanisms of anti-inflammatory effects and glucocorticoid resistance. J Complement Integr Med. 12:1–13. 2015.PubMed/NCBI View Article : Google Scholar
80	Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ and Adcock IM: Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med. 203:7–13. 2006.PubMed/NCBI View Article : Google Scholar
81	Payne DN and Adcock IM: Molecular mechanisms of corticosteroid actions. Paediatr Respir Rev. 2:145–150. 2001.PubMed/NCBI View Article : Google Scholar
82	Ogawa S, Lozach J, Benner C, Pascual G, Tangirala RK, Westin S, Hoffmann A, Subramaniam S, David M, Rosenfeld MG and Glass CK: Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell. 122:707–721. 2005.PubMed/NCBI View Article : Google Scholar
83	Li L, Sun J, Xu C, Zhang H, Wu J, Liu B and Dong J: Icariin ameliorates cigarette smoke induced inflammatory responses via suppression of NF-κB and modulation of GR in vivo and in vitro. PLoS One. 9(e102345)2014.PubMed/NCBI View Article : Google Scholar